利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.022 秒)

    METHODS FOR THE DETECTION OF ANTIBODIES AGAINST MEMBERS OF THE CARDIAC RECEPTOR FAMILY
    13.
    发明公开
    METHODS FOR THE DETECTION OF ANTIBODIES AGAINST MEMBERS OF THE CARDIAC RECEPTOR FAMILY 审中-公开
    检测对心脏受体家族成员的抗体的方法

    公开(公告)号：EP3234615A1

    公开(公告)日：2017-10-25

    申请号：EP15820130.1

    申请日：2015-12-21

    申请人： Schomburg, Lutz

    发明人： SCHOMBURG, Lutz ,  MINICH, Waldemar ,  BECKER, Niels-Peter

    IPC分类号： G01N33/94

    CPC分类号： G01N33/9433 ,  G01N33/944 ,  G01N2800/32

    摘要： The present invention relates to methods for the detection of antibodies against members of the cardiac receptor family; kits for performing the methods of the invention; the use of the methods of the invention for the diagnosis, therapy and/or prophylaxis of one or more diseases, which are related to one or more members of the cardiac receptor family, and the use of the methods of the invention for a) the identification of modulators of the binding properties of antibodies against members of the cardiac receptor family orb) the identification of therapeutic agents for the treatment of one or more of the said diseases.

    摘要翻译： 本发明涉及检测针对心脏受体家族成员的抗体的方法; 用于执行本发明的方法的试剂盒; 本发明的方法用于诊断，治疗和/或预防与心脏受体家族的一个或多个成员有关的一种或多种疾病，以及本发明的方法用于a） 鉴定针对心脏受体家族成员的抗体的结合特性的调节剂或b）鉴定用于治疗一种或多种所述疾病的治疗剂。

    QUANTIFICATION OF BOTULINUM TOXIN
    17.
    发明公开
    QUANTIFICATION OF BOTULINUM TOXIN 无效
    肉毒杆菌毒素的定量

    公开(公告)号：EP1597584A1

    公开(公告)日：2005-11-23

    申请号：EP04713111.5

    申请日：2004-02-20

    申请人： Ipsen Limited

    发明人： PICKETT, Andrew Martin,Ipsen Limited ,  QUIRK, Robin Andrew,Regence Limited ,  FRANCE, Richard Melville,Regentec Limited ,  RICCALTON-BANKS, Lisa Anne,Regentec Limited

    IPC分类号： G01N33/68 ,  G01N33/94 ,  G01N33/50

    CPC分类号： G01N33/944 ,  G01N33/5088

    摘要： The invention relates to a method for determining the quantity of pre-synaptic neuromuscular blocking substance (notably botulinum toxin) contained in a sample. In one aspects, the method comprises the following steps: (i) determining the minimum voltage Vm needed to induce the contraction of muscle tissue, said muscle tissue being connected to an electrical stimulator through a motor nerve and preferably immersed in an oxygenated physiological buffer containing glucose; (ii) adding the sample containing the pre-synaptic neuromuscular blocking substance; (iii) electrically stimulating, at a voltage at least equal to Vm, the muscle tissue at certain time intervals; (iv) comparing the effect induced by the sample to the effect induced by a reference substance and thereby determining the quantity of the pre-synaptic neuromuscular blocking substance in the sample.

    METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT
    19.
    发明公开
    METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT 有权
    方法和组合物治疗疼痛

    公开(公告)号：EP1133571A1

    公开(公告)日：2001-09-19

    申请号：EP99963940.4

    申请日：1999-11-22

    申请人： Proteome Sciences, Inc.

    发明人： CAMERON, Bruce, M., Sr. ,  ALLEN, Robert, C.

    IPC分类号： C12Q1/46 ,  A61K38/46

    CPC分类号： G01N33/523 ,  A61K38/465 ,  C12Q1/46 ,  C12Q2334/30 ,  C12Q2334/70 ,  C12Y301/01007 ,  G01N33/9406 ,  G01N33/944 ,  G01N2800/52 ,  Y10S435/975

    摘要： The present invention provides novel methods and diagnostic kits for the objective measurement of the severity of pain or stress being experienced by a patient with a disorder, diagnosis and treatment for patients suffering from painful disorders, and monitoring the effectiveness of different pain-treatment protocols. Pain-measuring methods comprise collecting a sample from a patient and determining the presence of a pain-associated marker in the sample. Methods for alleviating pain comprise administrating a dose of a therapeutically effective amount of a composition to the patient wherein the dose is determined by the presence of a pain-associated marker in a biological sample obtained from the patient. Compositions for alleviating pain comprise substances that are pain-associated markers or agents that interfere with pain-associated markers, and block or modulate the progression of pain perceived by the patient.